Following encouraging clinical results, retatrutide, a innovative peptide therapy for managing type 2 metabolic disorder, has secured regulatory approval from UK’s Medicines and Healthcare Agency (MHRA ). Initial availability is currently anticipated via dedicated weight management centres and certain NHS organisations in the year , with more ext